The report, put out following a nearly three-year probe, took issue with assertions by the pharmaceutical industry that high drug prices were needed to fund innovation and research and development programs.
The report, put out following a nearly three-year probe, took issue with assertions by the pharmaceutical industry that high drug prices were needed to fund innovation and research and development programs.
The report, put out following a nearly three-year probe, took issue with assertions by the pharmaceutical industry that high drug prices were needed to fund innovation and research and development programs.
Mallinckrodt Plc has defeated insurers' claims accusing the drugmaker of engaging in anticompetitive practices to inflate the price of one of its top products.
A group with antitrust claims against Mallinckrodt on Friday asked a Delaware bankruptcy judge to appoint an examiner to investigate what it claims are thousands of questionable votes cast for the drugmaker's Chapter 11 plan on behalf of asbestos injury claimants.